Index

Experimental group (М ± m)

Control group (М ± m)

n (number of patients)

25

20

Age (years)

23.9 ± 1.9

25.4 ± 2.2

BMI (kg/m²)

30.7 ± 0.6

30.7 ± 0.6

Fasting plasma glucose (mmol/l)

4.8 ± 0.09

4.6 ± 0.08

Basal insulin (pmol/l)

137.3 ± 5.6

147.3 ± 7.2

Stimulated insulin (pmol/l)

591.4 ± 9.1

579.2 ± 8.7

HOMA-IR

5.7 ± 1.0

5.9 ± 1.0

Testosterone (ng/ml) (n = 8)

0.89 ± 0.05

0.97 ± 0.07

Estradiol (pmol/l)

239 ± 25.9

216 ± 23.4

Progesterone (nmol/)

4.06 ± 0.08

4.86 ± 0.08

LH/FSH

2.50 ± 0.13

2.60 ± 0.16

17-OHP (ng/ml)

2.87 ± 0.15

2.13 ± 0.11

Average ovarial volume, ml

12.4 ± 1.9

11.1 ± 1.6

Hyperinsulinemia, n (%)

25 (100%)

20 (100%)

BMI > 25 kg/m², n (%)

8 (33%)

7 (33%)

Androgenic dermopathy, n (%)

7 (28%)

5 (25%)

Hyperlipidemia, n (%)

6 (24%)

6 (30%)

Acanthosis nigricans, n (%)

4 (16%)

2 (10%)

IGT, n (%)

3 (12%)

1 (5%)

IFG, n (%)

2 (8%)

2 (10%)

Heterozygous carrier for 21-hydroxylase defect

4 (8.9%)

-